NCT03034200 2024-11-26
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
5 trialsNCT03394027 2022-08-23
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02609230 2021-06-04
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Fox Chase Cancer Center
Phase 1 Completed
NCT02250781 2019-05-22
Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT02324621 2019-05-22
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed